Page last updated: 2024-12-09

2-(3,4-dimethoxyphenyl)-1-(2,4,6-trihydroxyphenyl)ethanone

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

You're asking about a compound with a rather complex name! Let's break it down:

**2-(3,4-dimethoxyphenyl)-1-(2,4,6-trihydroxyphenyl)ethanone** is a chemical compound that has several important features:

* **Structure:** The name tells us the compound's structure. It is an **ethanone** (also known as acetophenone) with two aromatic rings attached.
* One ring is a **3,4-dimethoxyphenyl**, meaning it's a benzene ring with two methoxy groups (CH3O-) at positions 3 and 4.
* The other ring is a **2,4,6-trihydroxyphenyl**, meaning it's a benzene ring with three hydroxyl groups (OH-) at positions 2, 4, and 6.
* These two rings are connected to the ethanone group through the carbon atoms at positions 1 and 2 of the ethanone.

**Importance for Research:**

This compound is likely important for research because it possesses interesting features that could be relevant in various fields:

* **Pharmacological Activity:** The combination of methoxy and hydroxy groups on the aromatic rings often leads to compounds with significant pharmacological activity. This could include:
* **Antioxidant Activity:** The hydroxyl groups can act as free radical scavengers, offering potential benefits in fighting oxidative stress.
* **Anti-inflammatory Activity:** The compound might possess anti-inflammatory properties, potentially useful in treating conditions like arthritis.
* **Enzyme Inhibition:** The compound's structure could interact with specific enzymes, potentially influencing their activity.

* **Material Science:** The presence of aromatic rings and functional groups like methoxy and hydroxy can contribute to:
* **Photoluminescence:** The compound might exhibit fluorescence properties, making it suitable for applications in materials science.
* **Polymer Synthesis:** The compound could be incorporated into polymers, modifying their properties like conductivity or mechanical strength.

* **Synthetic Chemistry:** The compound itself could be a valuable building block for synthesizing other more complex molecules with unique properties.

**To understand the specific importance of this particular compound, you would need more context:**

* **Where did you encounter this compound?** Was it mentioned in a research paper, a patent, or another scientific resource?
* **What is the specific research area or application?** Knowing the context helps understand the significance of the compound in that specific field.

**To find more information, I recommend:**

* **Searching scientific databases:** Databases like PubChem, SciFinder, and Reaxys can provide detailed information on the compound, including potential applications, biological activity, and synthesis routes.
* **Consulting research articles:** If the compound is mentioned in a specific paper, reading the paper can provide insights into its significance in the context of the research.

Cross-References

ID SourceID
PubMed CID804849
CHEMBL ID551196
CHEBI ID120760

Synonyms (20)

Synonym
MLS000530610 ,
2-(3,4-dimethoxyphenyl)-1-(2,4,6-trihydroxyphenyl)ethanone
smr000135588
OPREA1_722105
CHEBI:120760
AKOS000275877
CHEMBL551196
STK856112
HMS2392K03
F1190-0466
53084-06-3
ethanone, 2-(3,4-dimethoxyphenyl)-1-(2,4,6-trihydroxyphenyl)-
cambridge id 7112640
OPERA_ID_731
Q27208898
SR-01000251542-1
sr-01000251542
DTXSID50355532
2,4,6-trihydroxy-3',4'-dimethoxydeoxybenzoin
mfcd03266554
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
stilbenoidAny olefinic compound characterised by a 1,2-diphenylethylene backbone.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (12)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, MAJOR APURINIC/APYRIMIDINIC ENDONUCLEASEHomo sapiens (human)Potency0.05010.003245.467312,589.2998AID2517
LuciferasePhotinus pyralis (common eastern firefly)Potency19.01150.007215.758889.3584AID588342
thioredoxin reductaseRattus norvegicus (Norway rat)Potency1.25890.100020.879379.4328AID588453
ATAD5 protein, partialHomo sapiens (human)Potency23.10930.004110.890331.5287AID504467
GLS proteinHomo sapiens (human)Potency35.48130.35487.935539.8107AID624170
thioredoxin glutathione reductaseSchistosoma mansoniPotency89.12510.100022.9075100.0000AID485364
bromodomain adjacent to zinc finger domain 2BHomo sapiens (human)Potency10.00000.707936.904389.1251AID504333
euchromatic histone-lysine N-methyltransferase 2Homo sapiens (human)Potency39.81070.035520.977089.1251AID504332
lysosomal alpha-glucosidase preproproteinHomo sapiens (human)Potency39.50680.036619.637650.1187AID2100
15-hydroxyprostaglandin dehydrogenase [NAD(+)] isoform 1Homo sapiens (human)Potency31.62280.001815.663839.8107AID894
histone-lysine N-methyltransferase 2A isoform 2 precursorHomo sapiens (human)Potency31.62280.010323.856763.0957AID2662
Guanine nucleotide-binding protein GHomo sapiens (human)Potency39.81071.995325.532750.1187AID624288
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (5)

Processvia Protein(s)Taxonomy
negative regulation of inflammatory response to antigenic stimulusGuanine nucleotide-binding protein GHomo sapiens (human)
renal water homeostasisGuanine nucleotide-binding protein GHomo sapiens (human)
G protein-coupled receptor signaling pathwayGuanine nucleotide-binding protein GHomo sapiens (human)
regulation of insulin secretionGuanine nucleotide-binding protein GHomo sapiens (human)
cellular response to glucagon stimulusGuanine nucleotide-binding protein GHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (2)

Processvia Protein(s)Taxonomy
G protein activityGuanine nucleotide-binding protein GHomo sapiens (human)
adenylate cyclase activator activityGuanine nucleotide-binding protein GHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (1)

Processvia Protein(s)Taxonomy
plasma membraneGuanine nucleotide-binding protein GHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (32)

Assay IDTitleYearJournalArticle
AID588460High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, Validation Compound Set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588460High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, Validation Compound Set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588460High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, Validation Compound Set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID588461High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, Validation compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588461High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, Validation compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588461High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, Validation compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588459High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, Validation compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588459High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, Validation compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588459High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, Validation compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID1794808Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).2014Journal of biomolecular screening, Jul, Volume: 19, Issue:6
A High-Throughput Assay to Identify Inhibitors of the Apicoplast DNA Polymerase from Plasmodium falciparum.
AID1794808Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).
AID427665Antioxidant activity assessed as DPPH radical scavenging activity incubated at 40 degC in dark after 30 mins2009Bioorganic & medicinal chemistry, Jul-01, Volume: 17, Issue:13
Potential antioxidants and tyrosinase inhibitors from synthetic polyphenolic deoxybenzoins.
AID427661Antioxidant activity assessed as inhibition of FeCl2-induced lipid peroxidation by thiocyanate method2009Bioorganic & medicinal chemistry, Jul-01, Volume: 17, Issue:13
Potential antioxidants and tyrosinase inhibitors from synthetic polyphenolic deoxybenzoins.
AID427664Antioxidant activity assessed as ABTS radical scavenging activity2009Bioorganic & medicinal chemistry, Jul-01, Volume: 17, Issue:13
Potential antioxidants and tyrosinase inhibitors from synthetic polyphenolic deoxybenzoins.
AID427662Antioxidant activity assessed as ferrous ion chelating effect after 10 mins2009Bioorganic & medicinal chemistry, Jul-01, Volume: 17, Issue:13
Potential antioxidants and tyrosinase inhibitors from synthetic polyphenolic deoxybenzoins.
AID427666Antioxidant activity assessed as superoxide anion radical scavenging activity by spectrophotometry2009Bioorganic & medicinal chemistry, Jul-01, Volume: 17, Issue:13
Potential antioxidants and tyrosinase inhibitors from synthetic polyphenolic deoxybenzoins.
AID427663Antioxidant activity assessed as potassium ferric cyanide ion reducing power after 10 mins by Oyaizu method2009Bioorganic & medicinal chemistry, Jul-01, Volume: 17, Issue:13
Potential antioxidants and tyrosinase inhibitors from synthetic polyphenolic deoxybenzoins.
AID1224864HCS microscopy assay (F508del-CFTR)2016PloS one, , Volume: 11, Issue:10
Increasing the Endoplasmic Reticulum Pool of the F508del Allele of the Cystic Fibrosis Transmembrane Conductance Regulator Leads to Greater Folding Correction by Small Molecule Therapeutics.
AID1159537qHTS screening for TAG (triacylglycerol) accumulators in algae2017Plant physiology, Aug, Volume: 174, Issue:4
Identification and Metabolite Profiling of Chemical Activators of Lipid Accumulation in Green Algae.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (10)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's2 (20.00)29.6817
2010's6 (60.00)24.3611
2020's2 (20.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.00

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.00 (24.57)
Research Supply Index2.40 (2.92)
Research Growth Index4.40 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.00)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other10 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]